background
herp
simplex
viru
describ
caus
respiratori
tract
infect
critic
ill
patient
individu
immunocompromis
continu
matter
debat
circumst
relev
pathogen
pneumon
role
critic
ill
investig
prospect
intervent
studi
compar
littl
systemat
data
avail
role
pneumon
outpati
autoimmun
diseas
mainten
regimen
immunosuppress
retrospect
review
chart
patient
rheumatoid
arthriti
vascul
system
lupu
erythematosu
sle
follow
outpati
clinic
german
univers
hospit
year
episod
admiss
ward
result
diagnosi
pneumoniapneumon
identifi
type
pneumonia
clinic
featur
retrospect
studi
result
patient
rheumatoid
arthriti
vascul
sle
admit
ward
diagnos
pneumoniapneumon
use
bronchoscopi
total
case
pulmonari
infect
associ
lower
respiratori
tract
identifi
among
case
suggest
caus
role
sole
agent
caus
pneumon
prove
clinic
respons
antivir
treatment
remain
case
appear
bystand
bacteri
infect
mainten
therapi
leflunomid
inhibit
assembl
vitro
associ
milder
cours
pneumon
one
patient
detect
associ
stronger
immunosuppress
regimen
vasculit
diseas
present
studi
analyz
frequenc
hallmark
case
associ
pneumon
occur
compar
larg
cohort
patient
rheumatolog
autoimmun
diseas
area
controversi
studi
provid
evid
caus
isol
pneumon
immunocompromis
studi
may
provid
estim
frequenc
relev
infect
bacteri
agent
outpati
autoimmun
diseas
reactiv
latenc
facial
nerv
ganglia
herp
simplex
viru
may
caus
tracheobronch
pneumon
featur
lifethreaten
respiratoryfailur
bilater
chang
thorac
imag
pneumon
compar
well
investig
critic
ill
patient
mechan
ventil
show
oropharyng
reactiv
viru
within
first
day
number
retroand
prospect
studi
set
presenc
cytologyproven
pneumon
shown
poorer
outcom
antivir
treatment
benefici
immunosuppress
patient
malign
organ
transplant
cytotox
treatment
variou
reason
larg
though
extrem
heterogen
group
patient
describ
develop
pneumon
data
diseas
subject
scarc
mainli
consist
anecdot
account
one
retrospect
studi
bronchoalveolar
lavag
bal
microbiologyvirolog
result
renal
transplant
patient
avail
recent
retrospect
studi
pneumon
patient
solid
tumor
publish
repres
first
systemat
approach
field
view
lack
data
goal
present
studi
investig
potenti
signific
pneumon
patient
mainten
regimen
ambulatori
immunosuppress
therefor
retrospect
analyz
admiss
pneumoniapneumon
compar
larg
cohort
outpati
rheumatoid
vasculit
connect
tissu
autoimmun
diseas
period
year
retrospect
studi
approv
local
ethic
committe
local
electron
databas
contain
patient
diagnos
discharg
summari
rheumatolog
outpati
clinic
affili
hospit
depart
intern
medicin
search
combin
term
rheumatologicvasculit
connect
tissu
diseas
pneumonia
pneumon
episod
posit
hit
review
sever
current
immunosuppress
treatment
score
follow
immunosuppress
medic
lowdos
prednison
mgd
azulfidinechloroquin
intermedi
prednison
mgd
prednison
mgdmethotrex
prednison
mgdleflunomid
cyclosporin
prednisonemycophenol
mofetil
prednison
mg
dazathioprin
strong
prednison
mgdmethotrex
prednison
mgdmethotrexateanakinra
prednison
mg
dmethotrexateleflunomid
prednison
mg
detanercept
prednison
mgdazathioprin
lower
dose
prednisoneazathioprineleukopenia
maxim
prednison
mgdcyclophosphamid
prednison
mgd
time
inhospit
treatment
patient
diagnos
treat
current
standard
clinic
practic
part
prospect
clinic
trial
regard
treatment
pneumonia
pneumon
fiberopt
bronchoscopi
fob
perform
deem
appropri
bronchoalveolar
lavag
bal
perform
bronchoscop
examin
materi
subsequ
centrifug
fixat
paraformaldehyd
stain
use
hematineosin
standard
microscop
examin
perform
bal
fluid
also
subject
viral
polymeras
chain
reaction
pcr
deem
appropri
alway
consist
test
cmv
cytomegali
viru
select
posit
case
immunohistochemistri
bal
perform
use
rabbit
polyclon
antibodi
dako
laboratori
denmark
bronchoscop
biopsi
perform
deem
appropri
process
use
standard
protocol
microbiolog
serolog
diagnost
perform
use
standard
protocol
statist
analysi
perform
use
prism
softwar
graph
pad
la
jolla
ca
unclear
extent
outpati
regimen
current
standard
immunosuppress
autoimmun
diseas
may
confer
risk
pneumon
retrospect
review
chart
patient
rheumatoid
arthriti
ancaassoci
vascul
system
lupu
erythematosu
sle
follow
year
nephrolog
rheumatolog
outpati
clinic
medic
policlin
lmu
univers
munich
studi
period
wardadmiss
patient
rheumatologicvasculiticconnect
tissu
autoimmun
diseas
occur
among
episod
admiss
outpati
clinic
present
respiratori
deterior
ultim
diagnos
due
pneumonia
pneumon
tabl
rough
estim
one
infer
incid
communityacquir
respiratori
infect
pneumon
requir
hospit
outpati
autoimmun
diseas
patient
patient
year
ie
per
year
patient
bronchoscopi
lavag
perform
diagnost
purpos
within
first
four
day
admiss
also
compris
pcr
analysi
therebi
total
six
patient
admiss
pneumonia
posit
dna
detect
alveolar
fluid
identifi
order
estim
degre
immunosuppress
strength
patient
popul
arbitrari
score
rang
form
appli
see
method
relev
clinic
imag
laboratori
data
six
patient
posit
dna
detect
bal
summar
tabl
two
case
case
viral
bacteri
fungal
agent
bal
pcr
found
imag
studi
suggest
pneumon
success
treat
acyclovir
lead
rapid
clinic
improv
case
initi
chest
radiograph
thorac
ct
show
diffus
infiltr
ground
glass
opac
repres
imag
shown
figur
b
infect
may
featur
macroscop
vulner
aspect
bronchial
mucosa
nonspecif
sign
figur
order
increas
diagnost
certainti
case
immunohistochem
stain
bronchioalveolar
cell
perform
prove
posit
figur
case
inclus
bodi
epitheli
cell
bal
present
diagnosi
case
isol
pneumon
support
respons
acyclovir
absenc
prolong
antibacteri
treatment
case
display
initi
coinfect
fungal
bacteri
agent
requir
prolong
mechan
ventil
imag
studi
compat
viral
pneumon
case
infiltr
suggest
bronchopneumonia
also
clearli
present
mucosa
macroscop
inflam
case
case
inclus
bodi
cytolog
studi
pursu
case
due
obviou
bronchopneumonia
patient
fatal
outcom
prolong
inhospit
stay
despit
adequ
antiinfect
treatment
includ
time
administr
acyclovir
case
differ
former
four
case
therein
bilater
groundglass
opac
present
thorac
ct
antivir
treatment
initi
case
high
viral
load
bal
fluid
ignor
given
detect
influenza
viru
aureu
ps
aeruginosa
patient
improv
antibacteri
treatment
alon
discharg
readmit
one
month
later
denovo
respiratori
deterior
result
need
intub
administr
seri
antimicrobi
cours
alway
exclud
acyclovir
ct
second
bal
show
ground
glass
opacitiesard
even
higher
viral
load
patient
die
ard
antivir
treatment
could
initi
case
featur
unilater
bronchopneumon
infiltr
treat
standard
antibacteri
regimen
mycobacterium
kansasii
grew
initi
bal
treatment
chang
accordingli
patient
recov
without
administr
antivir
area
controversi
first
two
case
provid
evid
select
patient
ascertain
sole
agent
relev
pathogen
pneumon
amen
treatment
case
reflect
absolut
number
percentag
given
base
case
inform
immunosuppress
regimen
reliabl
avail
order
estim
degre
immunosuppress
strength
patient
popul
arbitrari
score
rang
form
appli
see
method
abbrevi
bal
bronchoalveolar
lavag
fob
fiberopt
bronchoscopi
pna
pneumoniapneumon
ys
year
abbrevi
use
acyclo
acyclovir
ag
antigen
amphob
amphotericin
b
ard
adult
respiratori
distress
syndrom
aza
azathioprin
bal
bronchoalveolar
lavag
ceftaz
ceftazidim
ceftriax
ceftriaxon
cipro
ciprofloxacin
clari
clarithromycin
cpap
continu
posit
airway
pressur
ct
comput
tomographi
coag
neg
coagulas
neg
cyclo
cyclophosphamid
day
eri
erythromycin
fluc
fluconazol
genta
gentamycin
geqml
genom
equivalentsml
hht
hereditari
hemorrhag
telangiectasia
oslerweberrendu
syndrom
inh
isoniazid
lefl
leflunomid
linez
linezolid
mero
meropenem
metro
metronidazol
moxi
moxifloxacin
mtx
methotrex
pred
prednison
tazo
piperacillintazobactam
tobra
tobramycin
vanco
vancomycin
w
week
test
season
winter
test
discret
physician
perform
bronchoscopi
present
studi
patient
autoimmun
diseas
pneumoniapneumonti
offend
agent
could
found
case
remain
broad
spectrum
bacteria
fungi
virus
identifi
figur
note
one
case
pneumon
due
methotrex
two
case
like
due
bystand
agent
remain
four
case
compar
six
case
neither
detect
suspect
respect
sever
immunosuppress
significantli
higher
degre
immunosuppress
group
note
p
twosid
mannwhitney
analysi
figur
analysi
perform
includ
patient
reliabl
inform
mainten
immunosuppress
avail
order
exclud
select
bia
comparison
also
perform
use
subgroup
patient
proven
neg
bal
albeit
reach
level
signific
similar
trend
observ
similar
median
immunosuppress
sever
score
neg
group
data
shown
though
great
caution
must
appli
interpret
small
number
intrigu
patient
wegen
granulomatosi
vascul
strongest
immunosuppress
score
also
posit
bal
often
pneumonia
pneumon
rheumatoid
arthriti
sle
patient
pneumoniapneumon
also
milder
immunosuppress
regimen
score
tabl
patient
system
autoimmun
diseas
alter
immun
respons
due
action
immunosuppress
treatment
underli
condit
increas
risk
develop
opportunist
infect
among
respiratori
tract
involv
associ
potenti
advers
outcom
clinic
workup
respiratori
deterioimag
studi
case
figur
imag
studi
case
convent
chest
radiograph
diffus
interstit
pattern
b
highresolutionct
hrct
featur
small
pleural
effus
partial
atelectasi
right
lower
lobe
addit
distinct
groundglass
opac
c
fiberopt
bronchoscopi
imag
show
vulner
tracheobronchi
mucosa
multipl
spontan
bleed
stigmata
consist
gener
tracheobronchi
inflamm
immunohistochem
stain
fixat
cyotspun
obtain
bal
case
identifi
posit
cell
dark
brown
colour
figur
immunohistochem
stain
fixat
cyotspun
obtain
bal
case
identifi
posit
cell
dark
brown
colour
bottom
left
alveolar
macrophag
lymphocyt
degen
chang
ration
set
complic
fact
bacteri
fungal
viral
infecti
agent
also
pulmonari
flare
system
diseas
drugrel
pulmonari
toxic
must
taken
differenti
diagnosi
indic
rais
suspicion
pneumon
immunocompromis
patient
sever
respiratori
insuffici
combin
patholog
find
imag
studi
thorac
radiograph
show
segment
bilater
opac
pleural
effus
ct
may
show
groundglass
opac
focal
consolid
pleural
effus
especi
groundglass
opac
use
diagnost
hint
immunocompromis
suggest
either
opportunist
infect
due
pneumocysti
jirovecii
cmv
virus
noninfecti
differenti
diagnos
ground
glass
opac
review
pneumon
diagnosi
exclus
reli
clinic
plausibl
posit
viral
test
imag
studi
definit
clinic
relev
posit
viral
test
matter
controversi
recent
studi
patient
prolong
mechan
ventil
luyt
et
al
requir
combin
clinic
deterior
ii
detect
lower
respiratori
tract
either
pcr
cultur
iii
cytolog
histolog
evid
inclus
bodi
either
bal
fluid
biopsi
specif
defin
pneumon
viral
cultur
difficult
handl
pcr
bal
fluid
becom
popular
diagnost
tool
sinc
easili
perform
sport
high
sensit
specif
howev
may
lack
due
potenti
contamin
fluid
oropharyng
reactiv
may
even
occur
plain
bacteri
pneumonia
inde
luyt
studi
posit
pcr
result
also
cytologicalhistolog
evid
infect
convers
cytologicalhistolog
criteria
lack
sensit
illustr
fact
even
open
lung
biopsi
may
neg
case
autopsyproven
pneumon
theoret
point
view
viraemia
could
addit
specif
diagnost
tool
associ
mark
reduct
sensit
care
microbiolog
remain
virolog
workup
necessari
defin
exclus
isol
pneumon
unfortun
result
bacteri
sampl
often
fals
neg
due
inadequ
low
amount
materi
assay
insensit
prior
antibiot
use
name
also
illustr
case
pneumonia
studi
offend
agent
detect
despit
clinic
evid
infect
detect
primari
respons
lead
infecti
agent
patient
ambulatoryacquir
pneumoniapneumon
autoimmun
diseas
figur
detect
primari
respons
lead
infecti
agent
patient
ambulatoryacquir
pneumoniapneumon
autoimmun
diseas
rsv
respiratoy
syncyti
viru
b
immunosuppress
score
significantli
sever
patient
detect
bal
subject
without
clinic
laboratori
evid
assess
patient
reliabl
inform
immunosuppress
regimen
avail
p
mannwhitney
twosid
test
henc
possibl
fals
neg
bacteri
test
also
appli
caveat
case
centr
perform
viral
test
bal
fluid
influenza
routin
winter
concern
virus
adenoviru
coronaviru
centr
defin
standard
order
avoid
omiss
overtest
viral
load
bal
fluid
detect
pcr
correl
posit
presenc
cytologyhistologyproven
pneumon
neg
outcom
necessarili
help
establish
diagnosi
due
potenti
great
variat
sampl
condit
howev
intrigu
case
seri
treatment
leflunomid
show
viral
load
geqml
greater
detect
averag
median
case
respect
clinic
cours
prolong
day
prior
admiss
hospit
compar
mild
leflunomid
exhibit
antivir
effect
inhibit
assembl
viral
capsid
dnarepl
dosag
use
rheumat
patient
tempt
specul
leflunomid
might
led
shed
illassembl
virion
case
outlin
introduct
studi
pneumon
patient
variou
immunosuppress
condit
begin
emerg
present
studi
retrospect
analyz
admiss
pneumoniapneumon
compar
larg
cohort
outpati
autoimmun
diseas
mainten
regimen
immunosuppress
although
consider
limit
retrospect
design
must
born
mind
data
provid
perspect
frequenc
bacteri
fungal
viral
agent
lead
pulmonari
infect
patient
group
respiratori
deterior
pneumonia
lead
hospit
admiss
common
event
outpati
autoimmun
diseas
treat
current
standard
immunosuppress
regimen
acut
lifethreaten
respiratori
failur
associ
detect
lower
respiratori
tract
rare
signific
find
base
find
diagnost
virolog
workup
particular
patient
cohort
includ
start
without
delay
treatment
area
controversi
provid
evid
immunocompromis
patient
may
develop
condit
accur
describ
pneumon
appear
amen
treatment
